Lexeo Therapeutics

LXEO · NASDAQ

$3.02+$0.26 (+9.42%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $2.76

Latest news

Press releaseOct 1, 9:00 AM ETGlobe Newswire
Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)
Press releaseSep 23, 8:00 AM ETPRNewswire
Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia
Press releaseSep 22, 7:00 AM ETGlobe Newswire
Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia
Press releaseAug 12, 7:00 AM ETGlobe Newswire
Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights
Press releaseAug 5, 7:00 AM ETGlobe Newswire
Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy
Press releaseJun 17, 4:01 PM ETGlobe Newswire
Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia
NewsJun 15, 11:32 AM ETVandana Singh
Why Is Lexeo Therapeutics Stock Gaining Monday?
Press releaseJun 15, 7:00 AM ETGlobe Newswire
Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia
Press releaseMay 19, 7:00 AM ETGlobe Newswire
Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
Press releaseMay 11, 7:00 AM ETGlobe Newswire
Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights
Press releaseApr 27, 5:15 PM ETGlobe Newswire
Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Press releaseMar 30, 4:05 PM ETGlobe Newswire
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Press releaseMar 3, 7:30 AM ETGlobe Newswire
Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference
Press releaseFeb 5, 7:30 AM ETGlobe Newswire
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February
NewsJan 12, 12:26 PM ETAvi Kapoor
Gold Rises Sharply; Lyra Therapeutics Shares Plunge
Press releaseJan 12, 7:00 AM ETGlobe Newswire
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy
NewsJan 9, 12:35 PM ET
10 Health Care Stocks Whale Activity In Today's Session
Press releaseDec 22, 7:30 AM ETGlobe Newswire
Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Press releaseDec 4, 8:00 AM ETGlobe Newswire
Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum
Press releaseOct 21, 9:20 AM ETPRNewswire
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Press releaseOct 8, 10:58 AM ETPRNewswire
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
Press releaseOct 7, 6:00 AM ETGlobe Newswire
Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy
NewsSep 24, 1:06 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsSep 4, 2:50 PM ETVandana Singh
FDA Outlines Process To Speed Up Rare Disease Therapy Approvals
NewsApr 9, 1:06 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
Press releaseApr 7, 6:00 AM ETGlobe Newswire
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study
NewsMar 24, 1:06 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
Press releaseJan 7, 7:30 AM ETGlobe Newswire
Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Press releaseDec 2, 7:00 AM ETBusiness Wire
Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024
NewsNov 13, 4:05 PM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Press releaseOct 30, 6:14 AM ETGlobe Newswire
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference
Press releaseSep 5, 7:30 AM ETGlobe Newswire
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
NewsJul 15, 2:32 PM ETAvi Kapoor
Crude Oil Moves Lower; Goldman Sachs Posts Upbeat Results
NewsJul 15, 1:23 PM ETAvi Kapoor
Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
NewsJul 15, 12:05 PM ETAvi Kapoor
Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet
NewsJul 15, 9:47 AM ETAvi Kapoor
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Falls In July
Press releaseJul 15, 6:00 AM ETGlobe Newswire
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)

Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia

Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia

Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy

Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

Why Is Lexeo Therapeutics Stock Gaining Monday?

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights

Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference

Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February

Gold Rises Sharply; Lyra Therapeutics Shares Plunge

Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy

10 Health Care Stocks Whale Activity In Today's Session

Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions

Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy

12 Health Care Stocks Moving In Wednesday's Intraday Session

FDA Outlines Process To Speed Up Rare Disease Therapy Approvals

12 Health Care Stocks Moving In Wednesday's Intraday Session

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

12 Health Care Stocks Moving In Monday's Intraday Session

Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Crude Oil Moves Lower; Goldman Sachs Posts Upbeat Results

Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet

Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Falls In July

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy